Introduction
Eugenol, the main component in the essential oils extracted from cloves, has been used in dental clinics as an analgesic (Markowitz et al., 1992) . Extensive studies to unveil the painrelieving mechanism of eugenol have found that the chemical potently inhibits diverse ion channels expressed in trigeminal ganglion (TG) neurons that sense dental pain (Lee et al., 2005; Park et al., 2006; Kim et al., 2011) . In particular, voltageactivated Na 1 channels and high voltage-activated (HVA) Ca 21 channels have been implicated as eugenol's molecular targets for lessening pain (Lee et al., 2005; Park et al., 2006) . In addition to those ion channels, low-voltage-activated (LVA) T-type channel currents in TG neurons have been detected by electrophysiological recordings (Borgland et al., 2001 (Borgland et al., , 2002 Ikeda and Matsumoto, 2003; Ross et al., 2009 ). Expression of T-type Ca 21 channels in TG neurons suggests that they might be involved in pain-sensing processes, a prominent role they play in dorsal root ganglion neurons (Bourinet et al., 2005; Jagodic et al., 2007 Jagodic et al., , 2008 Nelson et al., 2007) . The activation threshold of T-type channels is generally known to be lower than those of HVA Ca 21 channels as well as Na 1 channels (McCormick and Huguenard, 1992; Kim et al., 2001; Llinás and Steriade, 2006) . Thus, they could play a pivotal role in initiating depolarizing signals around resting membrane potentials, contributing to the generation of action potential in the coding of pain signals.
Molecular studies have uncovered that T-type Ca 21 channels are encoded by three different genes (Ca v 3.1, Ca v 3.2, and Ca v 3.3). Electrophysiological characterization has shown that the three isoforms begin to be activated around resting membrane potential. Ca v 3.1 and Ca v 3.2 channel currents have been characterized to have fast activating and inactivating kinetics in response to step-depolarizing potentials, whereas Ca v 3.3 has shown considerably slower activating and inactivating kinetics (Perez-Reyes, 2003) . Electrophysiological recordings and in situ hybridization detected distinctive physiologic roles and expression patterns of the three T-type channel isoforms. Recent experiments on Ca v 3.1-or Ca v 3.2-deficient mice further revealed that Ca v 3.1 is involved in visceral pain and rebound bursting in thalamic neurons (Kim et al., 2001 (Kim et al., , 2003 , whereas Ca v 3.2 is involved in peripheral pain processing via dorsal root ganglion neurons (Bourinet et al., 2005) and in maintenance of blood vessel tone (Chen et al., 2003) .
Although recordings of T-type channel currents have been reported in TG neurons (Borgland et al., 2001 (Borgland et al., , 2002 Ikeda and Matsumoto, 2003; Ross et al., 2009) , no previous studies have determined whether eugenol can inhibit T-type channel currents. Therefore, we examine how eugenol affects three T-type Ca 21 channel isoforms individually expressed in HEK293 cells. Our findings show that the analgesic dose dependently inhibits Ca v 3.1, Ca v 3.2, and Ca v 3.3 channel currents. The potency of eugenol for cloned T-type channel currents isoforms was similar to that for T-type currents recorded from rat TG neurons. These results strongly suggest that LVA T-type channels are potential molecular targets that help account for the dental analgesic's ability to relieve pain.
Materials and Methods
Chemicals. Most of the chemicals used for patch clamp recordings were purchased from Sigma-Aldrich (St. Louis, MO).
HEK293 Cell Culture and Expression of Ca v 3.1, Ca v 3.2, and Ca v 3.3 T-Type Ca 21 Channel Isoforms in HEK293 Cells. HEK293 cells that were stably transfected with cDNAs encoding rat Ca v 3.1, human Ca v 3.2, and rat Ca v 3.3 (Lee et al., 1999a) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum containing penicillin and streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a humidified atmosphere of 95% air/5% CO 2 . The stable cell lines were prepared in the morning before experiments as follows: cells were dissociated with treatment of 0.05% trypsin-EDTA (Invitrogen) for 2-3 minutes and then diluted 20-fold with Dulbecco's modified Eagle's medium, after which they were triturated and plated on coverslips coated with 0.1 mg/ml poly-L-lysine (Sigma-Aldrich) and maintained in a humidified CO 2 incubator.
Preparation of TG Neurons. TG neurons were isolated from 3-to 4-week-old Sprague-Dawley rats (Orient Bio, Inc., Gapyeong-City, Korea) using procedures approved by the Animal Care Committee of Sogang University. TG neurons were dissected out of the rat brain and cut into small pieces in Hanks' balanced salt solution (Invitrogen). TG neurons were incubated in 3 ml of Hanks' balanced salt solution containing 0.25% trypsin (Invitrogen) at 37°C for 30 minutes and then dissociated by trituration with sterile Pasteur pipettes. Subsequently, TG neurons were plated onto glass coverslips coated with 0.1 mg/ml poly-L-lysine (Sigma-Aldrich) and maintained in a humidified incubator supplied with 95% air/5% CO 2 at 37°C.
Electrophysiological Recording. Whole-cell patch clamp recordings were performed at room temperature using an Axopatch 200B patch-clamp amplifier (Molecular Devices, Foster City, CA), which was connected to a computer via a Digidata 1322A converter (Molecular Devices, Foster City, CA) and controlled using pCLAMP 9.2 software. Recording pipettes were pulled from TW-150-3 capillary tubing (World Precision Instruments, Sarasota, FL) and then fire polished. When filled with the internal solution, the resistance of the recording electrodes was 2-3 MV. The values of series resistance and capacitance were taken directly from readings of the amplifier after electronic subtraction of the capacitive transient. Series resistance was compensated to~75-80% using the prediction and compensation circuit. Giga seal formation and ruptured patch configuration were achieved in an external solution containing the following: 140 mM tetraethylammonium chloride, 2.5 mM CsCl, 10 mM BaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 10 mM glucose, pH 7.3 with TEAOH. The internal solution contained the following: 130 mM CsCl, 10 mM HEPES, 2 mM CaCl 2 , 10 mM EGTA, 5 mM MgATP, and pH 7.3 with CsOH. Ca v 3.1 and Ca v 3.2 currents were filtered at 2 kHz and sampled at 10 kHz, whereas Ca v 3.3 currents were filtered at 1 kHz and sampled at 5 kHz. Current amplitudes and exponential fits were obtained using Clampfit 9.2 software. Prism software (GraphPad, San Diego, CA) was used to fit activation and steady-state inactivation data with the Boltzmann equation. The smooth curve for channel activation was obtained by fitting the average data of chord conductance with a Boltzmann equation: G 5 1/{1 1 exp[(V 50 2 V)/ S act ]}, where V 50 is the potential for half-maximal activation and S act is the slope conductance. The curve for steady-state inactivation was derived from fitting normalized peak amplitudes against voltage with a Boltzmann equation: I/I max 5 1/[11exp (V 50,inact 2 V)/k], where V 50,inact is the potential for half-inactivation and k is the slope factor. Data are presented as mean 6 S.E.M. Differences were evaluated for significance using Student's unpaired t tests, with P , 0.05 (*), P , 0.01 (**), and P , 0.001 (***) as levels of significance.
Results
Eugenol Inhibition of Cloned Ca v 3 T-type Channel Isoforms. We first tested the ability of eugenol to inhibit T-type Ca 21 channel isoforms (Ca v 3.1, Ca v 3.2, and Ca v 3.3), each of which was stably transfected in HEK293 cells. Wholecell patch clamp recordings of T-type Ca 21 channel currents were performed in 10 mM Ba 21 solution as the charge carrier. When serial concentrations of eugenol solutions (100, 300, 1000, and 3000 mM) were cumulatively applied, currents generated through individual T-type isoforms were inhibited in a concentration-dependent manner (right panels of Fig. 1 , A-C). The time courses of T-type current inhibition by serial eugenol solutions displayed that eugenol inhibition was fast, reaching a steady state within 1 minute (left panels of Fig. 1 , A-C). All the T-type channel currents were strongly inhibited by 3 mM eugenol, more than ∼95%, and the inhibited currents were almost fully recovered within 2 minutes by washout. Small decrements in current amplitudes after washout were likely due to rundown (,10%). The dose-response curves were derived from fitting a Hill-Langmuir equation to the data. The IC 50 values for eugenol inhibition of Ca v 3.1, Ca v 3.2, and Ca v 3.3 T-type currents were estimated to be 463 6 12, 486 6 12, and 708 6 11 mM, respectively. Statistical analysis shows that Ca v 3.1 and Ca v 3.2 were more sensitively inhibited by eugenol than Ca v 3.3 (Student's unpaired t tests, P , 0.05; n 5 5-13; Fig. 1D ).
Eugenol Effects on Current Kinetics of T-type Ca v 3 Channels. We next examined whether eugenol could alter the current kinetics of Ca v 3.1, Ca v 3.2, and Ca v 3.3 T-type channel currents. When the current traces inhibited by eugenol (1 mM) were normalized to those before eugenol inhibition, the traces generated by Ca v 3.1 and Ca v 3.2 largely overlapped (Fig. 2 , A and B), suggesting that eugenol had little effect on the current kinetics of Ca v 3.1 and Ca v 3.2. We further analyzed Ca v 3.1 and Ca v 3.2 currents by fitting double exponentials to them, one corresponding to activation and the other to inactivation. No significant differences were detected in the activation and inactivation time constants of Ca v 3.1 and Ca v 3.2 currents before and after treatment with serial eugenol solutions (Fig. 2D) . On the contrary, the normalized Ca v 3.3 current traces before and after 1 mM eugenol treatment displayed that the inactivation kinetics of the Ca v 3.3 current was accelerated, whereas the activation kinetics was little altered (Fig. 2 , C-E). The accelerated inactivation kinetics of the Ca v 3.3 current was largely recovered by washout. Additional experiments and data analysis ( Fig. 2D) showed that 100 mM eugenol had little effect on the inactivation time constant of Ca v 3.3 currents, whereas 300 mM eugenol slightly decreased the inactivation time constant, which was further decreased by 1 mM eugenol (P , 0.05 and 0.01, Student's unpaired t test, n 5 5 or 6), suggesting that the inactivation kinetics of Ca v 3.3 currents is accelerated in a concentration-dependent manner. Consistently, analysis of current traces evoked by a current-voltage (I-V) protocol before and after 500 mM eugenol treatment displayed that eugenol accelerated the apparent inactivation kinetics of Ca v 3.3 currents at all the test potentials (P , 0.05, 0.01, or 0.001, Student's unpaired t-tests, n 5 5 or 6; Fig. 2E ).
A likely explanation is slow open channel block during the test pulse, as observed with ethosuximide (Gomora et al., 2001) .
Voltage-independent Inhibition of Ca v 3 T-type Channel Isoforms by Eugenol. Currents from HEK293 cells expressing Ca v 3.1, Ca v 3.2, or Ca v 3.2 channels were elicited by test pulses from a holding potential of 290 mV ranging between 270 mV and 140 mV by 10-mV increments. Representative current traces of Ca v 3.1, Ca v 3.2, and Ca v 3.3 before and after application of 500 mM eugenol are shown for comparison (Fig. 3, A-C) . Analysis of the I-V relationships (Fig. 3, D-F) showed that the eugenol inhibition percentages were similar over all test potentials, suggesting that eugenol inhibition of all T-type channel isoforms is voltage independent. Consistent with these results, eugenol (500 mM) did not significantly shift the activation curves of the three T-type channel isoforms (Fig. 4) .
Negative Shifts of Steady-State Inactivation Curves of T-type Channels by Eugenol. It has been reported that many drugs, including mibefradil, preferentially bind to inactivated state(s) of T-type channels (Martin et al., 2000) . 
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, where I is the normalized inhibition, IC 50 is the concentration of eugenol required for half-maximal inhibition, and n is the Hill coefficient. , and the average value inactivation time constants (t) are illustrated with bar graphs. Eugenol only accelerated the inactivation kinetics for Ca v 3.3 in a concentration-dependent manner (*P , 0.05 or **P , 0.01, Student's t test; n = 5 or 6). (E) Eugenol effects on the inactivation time constants of Ca v 3.3 currents evoked by various test potentials. Currents elicited by serial step pulses ranging from 270 mV to +40 mV from a holding potential of 290 mV were measured before and after treatment with application of 500 mM. Currents were fitted with two exponential equations [I = A 1 exp(2t/t 1 )+A 2 exp(2t/t 2 )+C], where t 1 is the inactivation time constant and t 2 is the activation time constant. Average inactivation tau (t) values before (s) and after 500 mM eugenol treatment (d) are plotted as a function of test potential. *P , 0.05, **P , 0.01, or ***P , 0.001) evaluated by Student's unpaired t tests (n = 5 or 6). Data represent the mean 6 S.E.M.
We thus examined whether eugenol modified the steady-state inactivation curves of T-type channel isoforms. Before and after application of 500 mM eugenol, channel availability was measured with a voltage step to 220 mV from varying prepulse potentials from 2110 to 245 mV (Fig. 4, A-C) . Smooth curves were obtained from fitting data to a Boltzmann equation, indicating that treatment of 500 mM eugenol negatively shifted the midpoint (V 50inact ) of voltage-dependence of inactivation for Ca v 3.1, Ca v 3.2, and Ca v 3.3 by 10.2, 7.4, and 8.6 mV, respectively (P , 0.05, Student's unpaired t-tests; n 5 6-8; Fig. 4, A-C) . The negative shifting effects almost disappeared after washing out the drug (data not shown). The negative shifting effects of channel availability by eugenol suggest that the drug likely binds preferentially to inactivated states of the T-type channel isoforms, thereby shifting the equilibrium away from states from which channels can open (Ertel and Cohen, 1994) .
Eugenol Binding to the Inactivated State of T-type Channel Isoforms. To evaluate further whether eugenol binds to the inactivated states of T-type channels, we applied a voltage protocol in which the holding potential was kept at 275 mV to induce ∼50% inactivation of the channel. , and Ca v 3.3 (C) before and after application of 500 mM eugenol were elicited by a voltage protocol composed of serial step pulses ranging from 270 mV to +40 mV by increments of 10 mV from a holding potential of 290 mV. (D-F) I-V relationships of Ca v 3.1, Ca v 3.2, and Ca v 3.3 channels before and after 500 mM eugenol treatment. Currents measured at various test potentials were normalized to the peak current at a test potential of 220 mV, and their normalized percentages are plotted against test potentials applied (n = 5-9). Eugenol inhibition percentages over different potentials are similar, suggesting that eugenol inhibition of T-type channel isoforms is voltage-independent. Fig. 4 . Eugenol effects on the activation and channel availability curves of T-type channels. Activation and steady-state inactivation curves of Ca v 3.1 (A, circles), Ca v 3.2 (B, triangles), and Ca v 3.3 (C, squares) are displayed from before (open symbols) and after 500 mM eugenol treatment (closed symbols). Channel activation levels depending on voltage are from the chord conductance values obtained by dividing current amplitudes by driving forces (reversal potential minus test potential), normalized to the peak conductance. The normalized chord conductance values were averaged and plotted against the test potentials. Smooth curves were obtained from fitting the data to the Boltzmann equation {G = 1/[1+exp (V 50,act 2 V)/k]}, where V 50,act is the half-activation voltage and k is a slope factor. The steady-state inactivation was evaluated by a two-step pulse protocol: A conditioning pulse of 10-second duration ranging from 2110 mV to 245 mV by increments of 5 or 10 mV was followed by a step to 220 mV test potential. Currents recorded at 220 mV after the serial conditioning potentials were normalized to the current amplitude recorded at a conditioning potential of 290 mV, and then average inactivation percentages were plotted as a function of prepulse potentials. The normalized data were then fit to the Boltzmann equation. Data represent the mean 6 S.E.M (n = 6-8). In Fig. 1 , the IC 50 values of eugenol for Ca v 3.1 and Ca v 3.2 were obtained at a stimulation frequency of 0.1 Hz. At an increased stimulation frequency of 0.2 Hz, the inhibition potency by eugenol (500 mM) for Ca v 3.1 and Ca v 3.2 was ∼50%, which is similar to the potency at 0.1 Hz. At higher test frequencies of 0.5 and 1 Hz, however, the inhibition percentages of Ca v 3.1 and Ca v 3.2 currents by 500 mM eugenol were significantly enhanced, indicating that eugenol inhibition of T-type channel isoforms is use dependent (Fig. 6) . One logical interpretation of the use-dependent inhibition profile of eugenol is that the drug preferentially binds to open and inactivated states of T-type channels isoforms.
Eugenol Inhibition Profile of T-type Currents Recorded from TG Neurons. Multiple publications have reported that T-type channels are expressed in TG neurons (Borgland et al., 2001 (Borgland et al., , 2002 Ikeda and Matsumoto, 2003; Ross et al., 2009) . To evaluate the sensitivity of eugenol on endogenous T-type currents, we recorded T-type currents from afferent neurons using whole-cell patch clamping. T-type currents displaying transient kinetics were predominantly elicited by a step pulse of 230 (or 240 mV) from a holding potential of290 mV, but small noninactivating currents were slightly contaminated in the whole currents. The noninactivating currents maintained even during the second step pulse, followed by an intervening step potential of 260 mV, are likely to be those passing through HVA calcium channels. Application of serial concentrations of eugenol inhibited T-type currents evoked by step pulses of 230 mV in a concentration-dependent manner. In comparison, noninactivating HVA currents, which were similarly evoked by the second pulse of 230 mV in amplitude, were less sensitively inhibited by the drug than T-type currents. For example, 1 mM eugenol inhibited T-type current by 70∼80%, but it inhibited HVA current by 40∼45%. Analysis of data showed that the IC 50 value for the TG T-type current is 498.5 6 14 mM (n 5 3-5; Fig. 7 ). These data indicate that eugenol inhibition sensitivity for TG T-type current is similar to the values for Ca v 3.1 and Ca v 3.2.
Nickel-sensitive Inhibition of T-type Currents in TG Neurons. Previous nickel blocking studies of recombinant T-type channel isoforms have established that Ca v 3.2 is sensitively blocked by low concentrations of nickel (IC 50 5 5∼12 mM), whereas Ca v 3.1 and Ca v 3.3 require much higher concentrations of nickel to be blocked (IC 50 for Ca v 3.1 5 250∼305 mM; IC 50 for Ca v 3.3 5 216 mM) (Lee at al., 1999b; Kang et al., 2006) . Based on the nickel sensitivity, we attempted to evaluate which T-type channel isoforms are mainly expressed in TG neurons. Application of serial Ni 21 solutions diminished T-type currents in a concentrationdependent manner and the IC 50 for nickel blockade was estimated to be 15.2 6 1.2 mM (n 5 4-6; Fig. 8 ). These findings suggest that T-type currents in rat TG neurons mainly arise from nickel-sensitive Ca v 3.2 isoforms, which may play crucial roles in mediating sensing processes of TG neurons. , where I is the normalized inhibition, IC 50 is the concentration of eugenol required for half-maximal inhibition, and n is the Hill coefficient.
Discussion
In this study, we determined the ability of eugenol to inhibit recombinant and endogenous T-type channels, which are potential molecular targets in TG sensory neurons. The IC 50 values of eugenol for recombinant Ca v 3.1, Ca v 3.2, and Ca v 3.3 channels were 485, 496, and 710 mM, respectively, suggesting that eugenol inhibits Ca v 3.1 and Ca v 3.2 more sensitively than it does Ca v 3.3. When T-type channel currents of TG neurons were recorded, the TG T-type currents showed transient kinetics that were more similar to the fast kinetics of Ca v 3.1 and Ca v 3.2 currents than to the slow kinetics of Ca v 3.3. Accordingly, the inhibition profile of eugenol for native T-type currents showed that the eugenol inhibition sensitivity for native T-type currents is similar to that for Ca v 3.1 and Ca v 3.2 rather than Ca v 3.3.
LVA T-type Ca 21 channels are known to be activated at lower threshold potential than voltage-gated Na 1 channels and HVA Ca 21 channels (Jahnsen and Llinás, 1984; McCormick and Huguenard, 1992; Llinás and Steriade, 2006) . In thalamic neurons, for example, a burst of action potentials can be triggered by low-threshold calcium spikes mediated by T-type Ca 21 channels. Inhibition of the calcium spikes by divalent metal ions can prevent triggering TTX-sensitive Fig. 6 . Use-dependent inhibition of T-type channel currents by eugenol. Ca V 3.1 (A), Ca V 3.2 (B), and Ca V 3.3 (C) currents were elicited by a step pulse of 220 mV from a holding potential of 290 mV with various frequencies of 0.2 Hz (u), 0.5 Hz (D), or 1 Hz (s). After current amplitude was stabilized, 500 mM eugenol was applied. The peak amplitudes of currents were normalized to the peak current amplitude before application of eugenol, and then the normalized average values (mean 6 S.E.M.) were plotted against time (n = 4 or 5). , where I is the normalized inhibition, IC 50 is the concentration of eugenol required for half-maximal inhibition, and n is the Hill coefficient. burst firing (Jahnsen and Llinás, 1984) . Based on the previous reports addressing lower activation threshold of T-type channels, our findings that eugenol inhibits LVA Ca v 3.1 and Ca v 3.2 isoforms more sensitively than HVA Ca 21 channels and Na 1 channels strongly suggest that LVA Ca 21 channels are more critical target proteins than Na 1 and HVA Ca 21 channels for the pain-relieving effects of eugenol.
We showed that the eugenol inhibition sensitivity for Ca v 3.1 and Ca v 3.2 was enhanced 2-to 3-fold by a change of holding potential from 290 to 275 mV to induce ∼50% inactivation of the channel (Fig. 5) . In native TG neurons, T-type channels seem to be inactivated by more than ∼50%, because the resting membrane potential of isolated TG neurons was previously found to be around 263 mV (Martenson et al., 1997) . We interpret that the eugenol sensitivity for Ca v 3.1 and Ca v 3.2 would be further enhanced by the depolarized conditions of TG neurons, thereby eugenol block of T-type currents contributes to eugenol's analgesic mechanism of action.
Comparison of biophysical properties of T-type channel isoforms before and after eugenol treatment demonstrated that eugenol negatively shifts the steady-state inactivation curves of three T-type channel isoforms in common. The negative shifting effects of eugenol significantly reduced the window currents, as illustrated by overlapping of the activation and steady-state inactivation curves (Fig. 3, A-C) . This would provide a second mechanism by which eugenol decreases the excitability of TG sensory neurons and contributes to its ability to relieve pain during dental treatment.
Because of its alleviation action of tooth pain, eugenol has been widely used as a local anesthetic agent in human dentistry (Markowitz et al., 1992) . In rat models, the agent has been demonstrated to be effective in relieving pain from orofacial regions and other peripheral regions (Park et al., 2009; Lionnet et al., 2010; Yeon et al., 2011) . For example, Park and his colleagues showed that subcutaneous injection of eugenol into the left vibrissa pad dose-dependently decreased the latency time of head withdrawal in response to thermal stimuli and application of eugenol onto inferior alveolar nerve reduced jaw-opening reflex in response to noxious electrical stimulation to anterial tooth pulp. They suggested that eugenol inhibited the formation of action potentials and the nerve conduction of sensory signals via blocking of diverse ion channels including voltage-gated Na 1 channels in TG neurons (Park et al., 2009 ).
Here we investigated the eugenol inhibition profiles for both cloned and endogenous T-type channels in TG neurons with their IC 50 values of ∼500 mM. Eugenol has been reported to inhibit multiple ion channels detected in TG neurons as follows: the IC 50 values for voltage-activated Na 1 channels, HVA Ca 21 channels, voltage-activated K 1 channels, and hyperpolarization-activated cation channels are ∼600 mM, 1 mM, 376 mM, and 157 mM, respectively (Lee et al., 2005; Park et al., 2006 Park et al., , 2009 Li et al., 2007; Yeon et al., 2011) . Taken together with the previous findings, we suggest that T-type channels are additional molecular targets for eugenol and therefore are likely to play a part in eugenol's underlying mechanism of analgesia. 
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, where I is the normalized inhibition, IC 50 is the concentration of nickel required for half-maximal inhibition, and n is the Hill coefficient.
